SCHEMBL1925330

SCHEMBL1925330

Cc1cc(-c2cc(C(F)F)n3ncc(-c4ccncc4)c3n2)ccc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
HSD17B10 Q99714 2/20 0.42
POLB P06746 4/20 0.41
LMNA P02545 2/20 0.40
AHR P35869 1/20 0.40
KMT2A Q03164 5/20 0.39
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 7/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 1/20 0.39
USP2 O75604 2/20 0.38
TSHR P16473 2/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TLR4 O00206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924387 0.89 GRM2 (0.43) MAPTHSD17B10POLBLMNAKMT2A
SCHEMBL1924228 0.86 MAPT (0.61) MAPTHSD17B10POLBLMNAKMT2A
SCHEMBL1924696 0.85 MAPT (0.50) MAPTHSD17B10POLBLMNAAHR
SCHEMBL313733 0.81 KDM4E (0.57) MAPTHSD17B10POLBLMNAKMT2A
SCHEMBL1925952 0.79 MAPT (0.59) MAPTHSD17B10LMNAKMT2AMEN1
SCHEMBL1924803 0.78 MAPT (0.61) MAPTHSD17B10POLBLMNAKMT2A
SCHEMBL1926984 0.78 MAPT (0.47) MAPTHSD17B10POLBLMNAAHR
SCHEMBL312224 0.77 S1PR1 (0.39) MAPTHSD17B10LMNAKMT2AMEN1
SCHEMBL1924725 0.76 MAPT (0.58) MAPTHSD17B10POLBLMNAKMT2A
SCHEMBL1925549 0.76 MAPT (0.61) MAPTHSD17B10POLBLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885HSD17B10 3505/4885POLB 3144/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885HSD17B10 3505/4885POLB 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.